Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.22M | $2.20M | $958K | $1.50M | $1.88M | $4.05M |
| Revenue growth | — | — | — | — | — | 80.8% | -56.4% | 56.9% | 25.1% | 115.6% |
| Gross profit | — | — | — | — | -$639K | $1.42M | -$18.0K | $413K | $740K | $2.30M |
| Gross margin | — | — | — | — | -52.5% | 64.6% | -1.9% | 27.5% | 39.3% | 56.7% |
| Operating income | -$11.1M | -$18.8M | -$15.2M | -$22.2M | -$29.7M | -$53.7M | -$18.0M | -$25.1M | -$61.0M | -$51.1M |
| Operating margin | — | — | — | — | -2443.3% | -2444.3% | -1878.6% | -1672.4% | -3245.1% | -1260.8% |
| Net income | -$11.2M | -$19.4M | -$15.8M | -$22.4M | -$29.9M | -$64.1M | -$72.9M | -$27.8M | -$60.7M | -$50.2M |
| Net margin | — | — | — | — | -2461.5% | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
| EPS (diluted) | -$0.42 | -$0.64 | -$0.42 | -$0.44 | -$0.46 | -$0.72 | -$13.25 | -$3.75 | -$4.66 | -$1.65 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.52M | -$13.4M | -$11.6M | -$19.7M | -$26.0M | -$35.9M | -$45.6M | -$23.3M | -$20.7M | -$22.2M |
| Capital expenditures | $106K | $91.0K | $31.0K | $918K | $1.23M | $2.25M | $4.34M | $281K | $516K | $3.19M |
| Free cash flow | -$7.63M | -$13.5M | -$11.7M | -$20.6M | -$27.2M | -$38.2M | -$49.9M | -$23.6M | -$21.2M | -$25.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.2M | $7.60M | $8.03M | $22.1M | $7.14M | $32.9M | $20.0M | $9.43M | $8.64M | $11.6M |
| Total assets | $14.4M | $10.2M | $9.52M | $39.9M | $55.4M | $160M | $100M | $74.9M | $35.1M | $25.8M |
| Total liabilities | $4.58M | $5.81M | $6.09M | $9.02M | $21.9M | $94.3M | $60.5M | $49.3M | $47.4M | $57.2M |
| Long-term debt | — | $1.87M | — | — | — | — | — | — | — | — |
| Shareholders' equity | $9.86M | $4.40M | $3.42M | $30.8M | $33.5M | $65.2M | $34.3M | $20.5M | -$12.3M | -$31.5M |
| Retained earnings | -$35.3M | -$54.7M | -$71.3M | -$93.7M | -$124M | -$188M | -$261M | -$290M | -$351M | -$401M |
| Shares (wtd avg diluted) | 28.7M | 31.5M | 40.7M | 57.0M | 69.1M | 88.9B | 5.54M | 7.65M | 13.1M | 30.5M |
Every figure is extracted from Insight Molecular Diagnostics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.